Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below Fifty Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s stock price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $4.07 and traded as low as $3.87. Voyager Therapeutics shares last traded at $3.98, with a volume of 729,899 shares traded.

Analysts Set New Price Targets

VYGR has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (d)” rating on shares of Voyager Therapeutics in a research report on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Finally, HC Wainwright lowered their target price on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $13.75.

Voyager Therapeutics Price Performance

The business’s 50 day simple moving average is $4.07 and its 200-day simple moving average is $4.05. The stock has a market capitalization of $216.84 million, a P/E ratio of -1.81 and a beta of 1.28.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%.The company had revenue of $11.15 million for the quarter, compared to the consensus estimate of $7.86 million. Research analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC increased its stake in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after acquiring an additional 317,927 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Voyager Therapeutics in the first quarter valued at approximately $218,000. Acadian Asset Management LLC raised its holdings in Voyager Therapeutics by 863.3% in the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after purchasing an additional 206,758 shares during the period. Patriot Financial Group Insurance Agency LLC raised its holdings in Voyager Therapeutics by 10.0% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 121,098 shares of the company’s stock worth $377,000 after purchasing an additional 11,000 shares during the period. Finally, Privium Fund Management B.V. boosted its position in shares of Voyager Therapeutics by 16.6% during the second quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock worth $79,000 after purchasing an additional 3,596 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.